-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 6.4%
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 6.4%
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating)'s share price traded down 6.4% during trading on Tuesday . The stock traded as low as $0.98 and last traded at $1.02. 300,374 shares traded hands during trading, a decline of 91% from the average session volume of 3,483,830 shares. The stock had previously closed at $1.09.
Bright Minds Biosciences Stock Down 6.4 %
The company's 50 day moving average price is $1.03 and its 200-day moving average price is $1.14.
Get Bright Minds Biosciences alerts:Hedge Funds Weigh In On Bright Minds Biosciences
An institutional investor recently bought a new position in Bright Minds Biosciences stock. Jane Street Group LLC bought a new position in Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 24,701 shares of the company's stock, valued at approximately $37,000. Jane Street Group LLC owned approximately 0.21% of Bright Minds Biosciences at the end of the most recent reporting period. Institutional investors own 4.03% of the company's stock.
Bright Minds Biosciences Company Profile
(Get Rating)Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Featured Articles
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
- Should The Bancorp Make Your Small-Cap Watchlist for 2023?
- 3 Consumer Cyclical Stocks With Good Momentum
- Could Pinduoduo Be the Best Chinese Stock to Own?
- 3 Big Box Retail Bets for the Holidays
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating)'s share price traded down 6.4% during trading on Tuesday . The stock traded as low as $0.98 and last traded at $1.02. 300,374 shares traded hands during trading, a decline of 91% from the average session volume of 3,483,830 shares. The stock had previously closed at $1.09.
纳斯达克周二盘中股价下跌6.4%，盘中一度跌至0.98美元，最新报1.02美元。300,374股股票全天成交，较当日平均成交量3,483,830股下跌91%。该股此前收盘报1.09美元。
Bright Minds Biosciences Stock Down 6.4 %
光明之心生物科学公司股价下跌6.4%
The company's 50 day moving average price is $1.03 and its 200-day moving average price is $1.14.
该公司的50日移动均线价格为1.03美元，其200日移动均线价格为1.14美元。
Hedge Funds Weigh In On Bright Minds Biosciences
对冲基金对Bright Minds生物科学的看法
An institutional investor recently bought a new position in Bright Minds Biosciences stock. Jane Street Group LLC bought a new position in Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 24,701 shares of the company's stock, valued at approximately $37,000. Jane Street Group LLC owned approximately 0.21% of Bright Minds Biosciences at the end of the most recent reporting period. Institutional investors own 4.03% of the company's stock.
一家机构投资者最近买入了Bright Minds Biosciences股票的新头寸。简街集团(Jane Street Group LLC)提交给美国证券交易委员会(Securities&Exchange Commission)的最新Form 13F文件显示，该公司在第一季度购买了Bright Minds Biosciences Inc.(纳斯达克：毒品获得评级)的一个新头寸。该公司购买了24,701股该公司股票，价值约37,000美元。在最近一次报告期结束时，简街集团拥有Bright Minds Biosciences约0.21%的股份。机构投资者持有该公司4.03%的股份。
Bright Minds Biosciences Company Profile
Bright Minds生物科学公司简介
Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Bright Minds Biosciences Inc是一家临床前生物科学公司，开发5-羟色胺(5-HT)药物，以改善严重和改变生活的疾病患者的生活。该公司的选择性5-羟色胺受体激动剂组合包括5-HT2C、5-HT2A和5-HT2C/A，用于治疗癫痫、疼痛和神经精神病学。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
- Should The Bancorp Make Your Small-Cap Watchlist for 2023?
- 3 Consumer Cyclical Stocks With Good Momentum
- Could Pinduoduo Be the Best Chinese Stock to Own?
- 3 Big Box Retail Bets for the Holidays
- 免费获取StockNews.com关于Bright Minds生物科学(药物)的研究报告
- Ulta发布美好的财年前景，但这只股票现在是买入的吗？
- Bancorp应该入选2023年小盘股观察名单吗？
- 3势头良好的消费周期股
- 拼多多可能是最值得持有的中国股票吗？
- 节假日的三大零售赌注
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Bright Minds生物科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bright Minds Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧